# Bevacizumab in Adults With Recurrent Respiratory Papillomatosis (RRP)

> **NCT05797246** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **National Cancer Institute (NCI)** · enrollment: 21 (actual)

## Conditions studied

- Respiratory Tract Diseases
- Neoplasms
- Neoplasms by Histologic Type
- Neoplasms, Glandular and Epithelial
- Neoplasms, Squamous Cell
- Tumor Virus Infections
- Infections
- Virus Diseases
- DNA Virus Infections
- Pathologic Processes
- Disease Attributes
- Recurrence
- Papilloma
- Respiratory Tract Infections
- Papillomavirus Infections

## Interventions

- **DRUG:** Bevacizumab

## Key facts

- **NCT ID:** NCT05797246
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2023-08-02
- **Primary completion:** 2027-07-31
- **Final completion:** 2029-01-01
- **Target enrollment:** 21 (ACTUAL)
- **Last updated:** 2026-05-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05797246

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05797246, "Bevacizumab in Adults With Recurrent Respiratory Papillomatosis (RRP)". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT05797246. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*